SK287620B6 - Použitie IL-18 inhibítorov - Google Patents

Použitie IL-18 inhibítorov Download PDF

Info

Publication number
SK287620B6
SK287620B6 SK1089-2003A SK10892003A SK287620B6 SK 287620 B6 SK287620 B6 SK 287620B6 SK 10892003 A SK10892003 A SK 10892003A SK 287620 B6 SK287620 B6 SK 287620B6
Authority
SK
Slovakia
Prior art keywords
inhibitor
antibody
receptor
tnf
cardiomyopathy
Prior art date
Application number
SK1089-2003A
Other languages
English (en)
Slovak (sk)
Other versions
SK10892003A3 (sk
Inventor
Charles Dinarello
Benjamin Pomerantz
Leonid Reznikov
Alden Harken
Yolande Chvatchko
Original Assignee
Laboratoires Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono Sa filed Critical Laboratoires Serono Sa
Publication of SK10892003A3 publication Critical patent/SK10892003A3/sk
Publication of SK287620B6 publication Critical patent/SK287620B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SK1089-2003A 2001-01-29 2002-01-28 Použitie IL-18 inhibítorov SK287620B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01101959 2001-01-29
PCT/EP2002/000844 WO2002060479A1 (en) 2001-01-29 2002-01-28 Use of il-18 inhibitors for the treatment and/or prevention of heart disease

Publications (2)

Publication Number Publication Date
SK10892003A3 SK10892003A3 (sk) 2004-02-03
SK287620B6 true SK287620B6 (sk) 2011-04-05

Family

ID=8176323

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1089-2003A SK287620B6 (sk) 2001-01-29 2002-01-28 Použitie IL-18 inhibítorov

Country Status (32)

Country Link
US (1) US20040234523A1 (no)
EP (1) EP1355668B1 (no)
JP (2) JP4860897B2 (no)
KR (1) KR100857376B1 (no)
CN (1) CN1326562C (no)
AR (1) AR032422A1 (no)
AT (1) ATE380558T1 (no)
BG (1) BG66483B1 (no)
BR (1) BR0206819A (no)
CA (1) CA2435466C (no)
CY (1) CY1107203T1 (no)
CZ (1) CZ305653B6 (no)
DE (1) DE60224004T2 (no)
DK (1) DK1355668T3 (no)
EA (2) EA006767B1 (no)
EE (1) EE05534B1 (no)
ES (1) ES2295332T3 (no)
HK (1) HK1062810A1 (no)
HR (1) HRP20030609A2 (no)
HU (1) HU229164B1 (no)
IL (2) IL157024A0 (no)
ME (1) ME00549B (no)
MX (1) MXPA03006776A (no)
NO (1) NO331083B1 (no)
PL (1) PL213568B1 (no)
PT (1) PT1355668E (no)
RS (1) RS51125B (no)
SI (1) SI1355668T1 (no)
SK (1) SK287620B6 (no)
UA (1) UA80676C2 (no)
WO (1) WO2002060479A1 (no)
ZA (1) ZA200305439B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI373343B (en) 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using
WO2002031115A2 (en) 2000-10-11 2002-04-18 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
SI1622939T1 (sl) 2003-05-13 2012-06-29 Merck Serono Sa Akrivne variante il-18 vezavnega proteina in medicinske uporabe le-tega
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
JP4961559B2 (ja) * 2004-03-11 2012-06-27 友昭 星野 インターロイキン１８阻害剤を有効成分とする疾患の予防又は治療剤
PL2267024T3 (pl) 2005-06-03 2012-10-31 Ares Trading Sa Wytwarzanie rekombinowanego białka wiążącego IL-18
PL1891088T3 (pl) 2005-06-10 2012-03-30 Ares Trading Sa Sposób oczyszczania białka wiążącego IL-18
AU2008324814B2 (en) * 2007-11-05 2013-05-16 Solventum Intellectual Properties Company Identification of tissue for debridement
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
SG11201601717VA (en) * 2013-09-05 2016-04-28 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
AU2016227644B2 (en) * 2015-03-05 2022-06-16 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) and antibodies in inflammatory diseases
US11091795B2 (en) 2016-07-11 2021-08-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
EP0929311B8 (en) * 1996-09-12 2006-02-01 Idun Pharmaceuticals, Inc. INHIBITION OF APOPTOSIS USING INTERLEUKIN-1 beta-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS
EP0942925B1 (en) * 1996-12-06 2006-11-22 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1 beta converting enzyme
CA2282845A1 (en) * 1997-03-18 1998-09-24 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
DE19743687C1 (de) * 1997-10-06 1998-11-26 Henkel Kgaa Detergensgemische und deren Verwendung
AU4961499A (en) * 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
BR9816013A (pt) * 1998-09-01 2003-01-21 Hayashibara Biochem Lab Proteìna de ligação de interleucina-18
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
KR20010110667A (ko) * 1999-03-16 2001-12-13 추후보정 치환 2-아미노벤즈아미드 카스파제 저해제 및 그것의 용도
WO2000061542A1 (en) * 1999-04-09 2000-10-19 Cytovia, Inc. Caspase inhibitors and the use thereof
AU6078500A (en) * 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
TWI373343B (en) * 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using
BRPI0110506B8 (pt) * 2000-05-05 2021-05-25 Applied Res Systems Ars Holding N V uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
YU57803A (sh) 2006-05-25
PL366802A1 (en) 2005-02-07
EA200501549A1 (ru) 2006-04-28
CY1107203T1 (el) 2012-11-21
PT1355668E (pt) 2008-01-04
UA80676C2 (en) 2007-10-25
HU229164B1 (en) 2013-09-30
CZ20032335A3 (en) 2004-07-14
HUP0303306A2 (hu) 2004-01-28
JP2009102354A (ja) 2009-05-14
BG66483B1 (bg) 2015-03-31
CN1499982A (zh) 2004-05-26
EA200300844A1 (ru) 2003-12-25
ATE380558T1 (de) 2007-12-15
CA2435466A1 (en) 2002-08-08
EE05534B1 (et) 2012-04-16
ME00549B (me) 2011-10-10
EP1355668A1 (en) 2003-10-29
BG108128A (bg) 2004-11-30
EA010180B1 (ru) 2008-06-30
CN1326562C (zh) 2007-07-18
DE60224004D1 (de) 2008-01-24
DK1355668T3 (da) 2008-05-05
IL157024A0 (en) 2004-02-08
SI1355668T1 (sl) 2008-06-30
NO20033228L (no) 2003-09-26
CA2435466C (en) 2012-04-03
AR032422A1 (es) 2003-11-05
CZ305653B6 (cs) 2016-01-27
HUP0303306A3 (en) 2005-12-28
HRP20030609A2 (en) 2005-06-30
IL157024A (en) 2014-02-27
EE200300328A (et) 2003-10-15
JP4860897B2 (ja) 2012-01-25
EP1355668B1 (en) 2007-12-12
NO331083B1 (no) 2011-10-03
JP2004522748A (ja) 2004-07-29
WO2002060479A1 (en) 2002-08-08
RS51125B (sr) 2010-10-31
PL213568B1 (pl) 2013-03-29
KR20030070143A (ko) 2003-08-27
US20040234523A1 (en) 2004-11-25
NO20033228D0 (no) 2003-07-16
KR100857376B1 (ko) 2008-09-05
DE60224004T2 (de) 2009-07-23
HK1062810A1 (en) 2004-11-26
ES2295332T3 (es) 2008-04-16
MXPA03006776A (es) 2003-10-24
BR0206819A (pt) 2004-02-03
ZA200305439B (en) 2004-07-15
EA006767B1 (ru) 2006-04-28
SK10892003A3 (sk) 2004-02-03

Similar Documents

Publication Publication Date Title
JP2009102354A (ja) 心疾患の治療および／または予防のためのｉｌ−１８阻害剤の使用
KR100877033B1 (ko) 패혈증의 치료 또는 예방을 위한 ｉｌ-18 저해물질의 용도
NO338682B1 (no) IL-18 bindingsprotein (IL-18BP), en sammensetning, fremgangsmåte for fremstilling samt anvendelse
HRP20040758A2 (en) Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases
SK15562002A3 (sk) Použitie IL-18 inhibítora, použitie expresného vektora obsahujúceho sekvenciu kódujúcu IL-18 inhibítor, použitie vektora na indukciu a/alebo zosilnenie endogénnej produkcie IL-18 inhibítora v bunke a použitie bunky s produkciou IL-18 inhibítora
US7304040B2 (en) Suppression of post-transplant arteriosclerosis
AU2002249144B2 (en) Use of IL-18 inhibitors for the treatment and/or prevention of heart disease
US5527775A (en) Reduction of mammalian neoplasms with phospholipase A2 activating substances
AU2002249144A1 (en) Use of IL-18 inhibitors for the treatment and/or prevention of heart disease

Legal Events

Date Code Title Description
TC4A Change of owner's name

Owner name: MERCK SERONO SA, COINSINS, VAUD, CH

Effective date: 20120709

MK4A Patent expired

Expiry date: 20220128